These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38762716)

  • 1. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
    BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron status in dogs with myxomatous mitral valve disease.
    Savarese A; Probo M; Locatelli C; Gazzonis AL; Zanzani SA; Traini G; Vitiello T; Brambilla PG
    Pol J Vet Sci; 2018 Sep; 21(3):507-515. PubMed ID: 30468339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
    Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
    PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myxomatous mitral valve disease and associated pulmonary hypertension might increase serum angiopoietin-2 in dogs.
    Yu H; Lee D; Chae Y; Choi M; Lee Y; Yun T; Kang BT; Yang MP; Kim H
    Am J Vet Res; 2024 Jun; 85(6):. PubMed ID: 38531156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
    J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
    Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
    J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
    BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C
    Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
    Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
    J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
    J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
    Kim HJ; Kim J; Kim S; Kim HJ
    BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-dimensional echocardiographic estimates of left atrial function in healthy dogs and dogs with myxomatous mitral valve disease.
    Dickson D; Caivano D; Matos JN; Summerfield N; Rishniw M
    J Vet Cardiol; 2017 Dec; 19(6):469-479. PubMed ID: 29111284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease.
    Vereb M; Atkins CE; Adin D; Blondel T; Coffman M; Lee S; Guillot E; Ward JL
    J Vet Intern Med; 2024; 38(1):51-60. PubMed ID: 37909399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
    Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
    Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of Oxidative Stress in Dogs with Myxomatous Mitral Valve Disease are Influenced by Sex, Neuter Status, and Serum Cholesterol Concentration.
    Reimann MJ; Häggström J; Møller JE; Lykkesfeldt J; Falk T; Olsen LH
    J Vet Intern Med; 2017 Mar; 31(2):295-302. PubMed ID: 28132441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
    Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
    J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG; Falk T; Teerlink T; Guðmundsdóttir HH; Sigurðardóttir S; Rasmussen CE; Olsen LH
    Vet J; 2011 Sep; 189(3):349-52. PubMed ID: 20822939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Müller S; Menciotti G; Borgarelli M
    J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of plasma and urinary levels of 6-keto-prostaglandin F1alpha as a marker for asymptomatic myxomatous mitral valve disease in dogs.
    Rasmussen CE; Sundqvist AV; Kjempff CT; Tarnow I; Kjelgaard-Hansen M; Kamstrup TS; Sterup AL; Soerensen TM; Olsen LH
    Vet J; 2010 May; 184(2):241-6. PubMed ID: 19324577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.